Novartis Foundation

MidOcean Partners Welcomes John Kahan to Executive Board

Retrieved on: 
Tuesday, August 1, 2023
Asset Management, Professional Services, Finance, Cloud, IBM, Problem solving, Mathematics, Marketing, Partner, Data analysis, Binghamton University, Business, Microsoft, MBA, Machine learning, New York University Stern School of Business, Artificial intelligence, Mannheim School of Computer Science and Mathematics, AI, Integration, Novartis Foundation, Marketing communications, Computer science, SMC, Data science, Management, MidOcean Partners, U.S. Venture Partners

MidOcean Partners (“MidOcean”), a premier New York-based alternative asset manager specializing in middle-market private equity and alternative credit investments, today announced that John B. Kahan, former Chief Data Analytics Officer of Microsoft Corporation (“Microsoft”), has joined the firm as an Operating Partner.

Key Points: 
  • MidOcean Partners (“MidOcean”), a premier New York-based alternative asset manager specializing in middle-market private equity and alternative credit investments, today announced that John B. Kahan, former Chief Data Analytics Officer of Microsoft Corporation (“Microsoft”), has joined the firm as an Operating Partner.
  • Mr. Kahan is a seasoned data science leader with nearly four decades of data science, global business, and technology transformation experience across some of the world’s leading technology companies, including Microsoft and IBM Corporation (“IBM”).
  • Erik Oken, Chairman of MidOcean’s Private Equity business said, “John is a data-driven leader with a wealth of experience across data analytics, customer relationship management, marketing and problem solving.
  • in Computer Science and Mathematics from Binghamton University and an MBA from the New York University Stern School of Business.

New urban health 'accelerator' aims to transform cardiovascular population health globally

Retrieved on: 
Monday, May 22, 2023
Blood pressure, Workforce, Male, Cardiovascular disease, CV, Stroke, Public, Workplace, World Health Assembly, Health, Splenic infarction, Hypertension, Death, Risk, Novartis Foundation, IntraHealth International, Accelerator, City, WHO, Paulo, World Health Organization, Pharmaceutical industry

The CARDIO4Cities Accelerator by Novartis Foundation and IntraHealth International aims to replicate the successful CARDIO4Cities approach in 30 major cities within three years to transform cardiovascular population health and equity globally.

Key Points: 
  • The CARDIO4Cities Accelerator by Novartis Foundation and IntraHealth International aims to replicate the successful CARDIO4Cities approach in 30 major cities within three years to transform cardiovascular population health and equity globally.
  • Experts say public-private partnerships are key to address the growing burden of cardiovascular disease, the world's leading cause of death, according to the World Health Organization (WHO)1.
  • The accelerator aims to replicate CARDIO4Cities, the cardiovascular (CV) population health approach pioneered and validated by the Novartis Foundation, in 30 major cities within the next three years.
  • As a neutral broker between city governments, health experts, industry, implementing partners, funders and investors, the accelerator pledges the global community to direct action and funding toward transforming CV population health and equity.

New urban health 'accelerator' aims to transform cardiovascular population health globally

Retrieved on: 
Monday, May 22, 2023
Blood pressure, Workforce, Male, Cardiovascular disease, CV, Stroke, Public, Workplace, World Health Assembly, Health, Splenic infarction, Hypertension, Death, Risk, Novartis Foundation, IntraHealth International, Accelerator, City, WHO, Paulo, World Health Organization, Pharmaceutical industry

The CARDIO4Cities Accelerator by Novartis Foundation and IntraHealth International aims to replicate the successful CARDIO4Cities approach in 30 major cities within three years to transform cardiovascular population health and equity globally.

Key Points: 
  • The CARDIO4Cities Accelerator by Novartis Foundation and IntraHealth International aims to replicate the successful CARDIO4Cities approach in 30 major cities within three years to transform cardiovascular population health and equity globally.
  • Experts say public-private partnerships are key to address the growing burden of cardiovascular disease, the world's leading cause of death, according to the World Health Organization (WHO)1.
  • The accelerator aims to replicate CARDIO4Cities, the cardiovascular (CV) population health approach pioneered and validated by the Novartis Foundation, in 30 major cities within the next three years.
  • As a neutral broker between city governments, health experts, industry, implementing partners, funders and investors, the accelerator pledges the global community to direct action and funding toward transforming CV population health and equity.

Stagwell (STGW) Marketing Cloud Taps Former Microsoft Chief Data Analytics Officer John Kahan, Code and Theory Chairman Dan Gardner as Advisors

Retrieved on: 
Monday, April 24, 2023
Cloud, SIDS, NFL, Stagwell, IBM, Petroleum, Weeping Angel, Seattle Children's, Cardiovascular disease, Microsoft, Los Angeles Times, Polar code (coding theory), Marketing, Government, Science, Washington Commanders, Maybelline, Burger King, Map, Novartis Foundation, SMC, Data science, Management, Pharmaceutical industry, Code, U.S. Venture Partners

NEW YORK, April 24, 2023 /PRNewswire/ -- Stagwell (NASDAQ: STGW) Marketing Cloud today announced the appointment of former Microsoft VP and Chief Data Analytics Officer John Kahan, and Stagwell's Code and Theory Network Executive Chairman Dan Gardner, to the newly created Stagwell Marketing Cloud (SMC) Advisory Council.

Key Points: 
  • NEW YORK, April 24, 2023 /PRNewswire/ -- Stagwell (NASDAQ: STGW) Marketing Cloud today announced the appointment of former Microsoft VP and Chief Data Analytics Officer John Kahan, and Stagwell's Code and Theory Network Executive Chairman Dan Gardner, to the newly created Stagwell Marketing Cloud (SMC) Advisory Council.
  • "Stagwell Marketing Cloud is a key component of Stagwell's approach to transforming marketing through impactful technology.
  • "The Stagwell Marketing Cloud is a key component of the larger technological transformation services our network can provide brand partners," said Gardner.
  • In addition to overseeing Code and Theory and its subsidiaries, Dan Gardner is an active investor across the media and technology landscape.

ImmunOs Therapeutics Appoints Dr. Hilmar Ebersbach as Vice President Antibody Development and Protein Engineering

Retrieved on: 
Monday, October 17, 2022
Protein engineering, HLA, Therapy, KIR, Molecular Partners, Degenerative disease, Antibody, Lightspeed Venture Partners, Patient, Biomedical Research, Novartis Foundation, Inflammation, Cancer, University, R, Immune system, Company, Doctor of Philosophy, Drug discovery, Martin Luther University College, Novartis Institute for Tropical Diseases, Immuno-psychiatry, University of Zurich, NIBR, Lab, Fine chemical, Biochemistry, MD, Biotechnology

Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA October 17, 2022 ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the appointment of Dr. Hilmar Ebersbach as Vice President Antibody Development and Protein Engineering (ADPE).

Key Points: 
  • Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA October 17, 2022 ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the appointment of Dr. Hilmar Ebersbach as Vice President Antibody Development and Protein Engineering (ADPE).
  • "Hilmar brings an excellent track record in protein engineering and drug discovery, especially regarding novel drug formats and conjugates.
  • "I believe that ImmunOs approach in myeloid checkpoint therapeutics is at the forefront of current scientific research," said Dr. Hilmar Ebersbach, Vice President ADPE at ImmunOs.
  • ImmunOs Therapeutics AG leverages its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases.

Global AI network aiming to improve urban heart health equity launches in New York City

Retrieved on: 
Monday, September 19, 2022
Degenerative disease, Urban Health Resource Centre, Time, Machine learning, Risk, Hospital, Novartis Foundation, City, Leprosy, NEW, University School, NYC Health + Hospitals, Population, Obesity, Data management, Partnership, Policy, Microsoft, Malaria, Health equity, Diabetes, New York City Department of Health and Mental Hygiene, Urban, CEO, Work, Cardiovascular disease, Board, Research, Data science, Education, Public health, Death, Housing, Medical device, Pharmaceutical industry, Dietary supplement, Paulo, Health

The AI4HealthyCities Health Equity Network was created by the Novartis Foundation and developed in collaboration with Microsoft AI for Health.

Key Points: 
  • The AI4HealthyCities Health Equity Network was created by the Novartis Foundation and developed in collaboration with Microsoft AI for Health.
  • In New York City, the initiative is run in partnership with the New York University School of Global Public Health; the public hospital system NYC Health + Hospitals; and the city health authorities.
  • The NYU School of Global Public Health will lead the research in collaboration with Microsoft AI for Health by bringing together data on cardiovascular disease and social determinants of heart health in New York City.
  • AI4HealthyCities is part of the Novartis Foundation's global vision to improve urban heart health and narrow health inequities.

Accenture Joins AI4BetterHearts Data Collaborative

Retrieved on: 
Tuesday, March 29, 2022
Data Management, Health, Technology, Software, General Health, Networks, Microsoft, CV, Population, Death, NYSE, Advanced technology, United States intelligence operations abroad, Interactivity, CVD, Operation, Cardiovascular disease, Health, Population health, Artificial intelligence, Technology, Novartis Foundation, List of life sciences, Policy, AI, Patient, Medical device, Accenture

Accenture (NYSE: ACN) has joined AI4BetterHearts, a global data collaborative founded by Microsoft and the Novartis Foundation, that aims to help stakeholders from policy makers to patients make better decisions about heart health and improve the health of entire populations.

Key Points: 
  • Accenture (NYSE: ACN) has joined AI4BetterHearts, a global data collaborative founded by Microsoft and the Novartis Foundation, that aims to help stakeholders from policy makers to patients make better decisions about heart health and improve the health of entire populations.
  • AI4BetterHearts leverages heart health data from different sources, using artificial intelligence (AI) and advanced analytics to better understand the drivers of CV health, including health inequities, in large populations.
  • Accenture joins the collaboration to further the development of AI insights that can help improve population-wide cardiovascular health outcomes.
  • "We are joining the AI4BetterHearts collaborative to help further its ambitions to prevent cardiovascular disease.

Domino Data Lab Appoints Data Science Leader John Kahan to Strategic Board Advisor Role

Retrieved on: 
Thursday, March 17, 2022
Cloud, Bing, Microsoft, Sequoia Capital, Marketing, Data science, IBM, Kahan, Board, SIDS, Petroleum, Cardiovascular disease, CEO, Health, Board of directors, Data analysis, Artificial intelligence, Enterprise, Industry, Seattle Children's, Movement, Solution, SAN, Engineering, Novartis Foundation, Management, Dominoes, U.S. Venture Partners

SAN FRANCISCO, March 17, 2022 /PRNewswire/ -- Domino Data Lab, provider of the leading Enterprise MLOps platform trusted by over 20% of the Fortune 100, today announced that John Kahan, Chief Data Analytics Officer Emeritus at Microsoft, has joined the company as a strategic advisor to both its CEO and Board of Directors. In his new role, Kahan will advise Domino's product development and go-to-market efforts.

Key Points: 
  • Kahan is a proven leader with nearly four decades of data science, worldwide business, and technology transformation experience across Microsoft and IBM.
  • "Our mission is to unleash data science to address the world's most important challenges," said Nick Elprin, co-founder and CEO of Domino Data Lab.
  • "John's passion about using data for good is inspiring, and his experience as an accomplished data science leader will be invaluable to helping us make Domino the best platform for enterprise data science teams."
  • Domino Data Lab powers model-driven businesses with its leading Enterprise MLOps platform that accelerates the development and deployment of data science work while increasing collaboration and governance.